Company
ACXP +1.41%Acurx Pharmaceuticals, Inc.
Market Cap: $6.2 Million
USD as of Aug 2, 2026
$ACXP +1.41% $ACXP United States Healthcare Biotechnology US Healthcare US BiotechnologyAcurx Pharmaceuticals, Inc. Market Capitalization Over Time
View HistoryEvolution of Acurx Pharmaceuticals, Inc. market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Financials
| Last Financial Reports Date | None |
| Revenue TTM | $None |
| EBITDA | $None |
| Gross Profit TTM | $None |
| Profit Margin | % |
| Operating Margin | % |
| Quarterly Revenue Growth | % |
Stocks & Indexes
Acurx Pharmaceuticals, Inc. main stocks and indexes inclusions.
$ACXPNASDAQ Composite